Profile: KaloBios Pharmaceuticals Inc (KBIO.OQ)
KaloBios Pharmaceuticals, Inc., incorporated on September 19, 2001, is a biopharmaceutical company. The Company focuses on developing medicines for patients with neglected and rare diseases, with an ancillary focus on pediatric conditions. The Company's product candidate is benznidazole, for the treatment of Chagas disease, a parasitic illness that can lead to long-term heart, intestinal and neurological problems. The Company is developing monoclonal antibodies, lenzilumab, for the treatment of chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) both of which are rare hematologic cancers. The Company is exploring development of another monoclonal antibodies (mAb), ifabotuzumab, for the treatment of rare solid and hematologic cancers. The Company's Humaneered technology platform is a method for converting existing antibodies (typically murine) into engineered human antibodies designed for therapeutic use, particularly for chronic conditions.
Lenzilumab is a recombinant antibody designed to target and neutralizes soluble granulocyte-macrophage colony-stimulating factor (GM-CSF), a central actor in leukocyte differentiation, autoimmunity and inflammation. The Company used Humaneered antibody development platform to develop lenzilumab. It is engaged in developing lenzilumab for use in patients with CMML and plans to investigate its use in patients with JMML depending on the results of studies in CMML. The GM-CSF receptor is expressed on myeloblasts and other progenitor cells, and binding results in differentiation and maturation into monocytes.
Ifabotuzumab is a Humaneered mAb in which the carbohydrate chains lack fucose, thereby enhancing the targeted cell-killing activity of the antibody. Ifabotuzumab binds to the EphA3 receptor, which plays a role in cell positioning and tissue organization during fetal development. EphA3 is a tyrosine kinase receptor expressed on the tumor cell surface in a number of hematologic malignancies and solid tumors, and is also expressed on the stem cell compartment. This compartment includes malignant stem cells, the vasculature that feeds them and the stromal cells that protect them. EphA3 expression has been documented in various tumor types, including acute myeloid leukemia (AML), chronic myelogenous leukemia, chronic lymphocytic leukemia, myelodysplastic syndrome (MDS), myelofibrosis, multiple myeloma, melanoma, breast cancer, non-small cell lung cancer, colorectal cancer, gastric cancer, renal cancer, glioblastoma and prostate cancer.
The Company's KB001 A, is a Humaneered, polyethylene glycol (PEG)ylated, anti Peanut Chlorotic Ringspot Virus (PcrV) modified antibody fragment (Fab) antibody developed for the prevention and treatment of Pseudomonas aeruginosa (Pa), infections in mechanically ventilated patients and cystic fibrosis (CF), patients with chronic Pa lung infections. KB001 A was designed to bind to and neutralize the pathogenicity of Pa, thereby allowing the body's natural immune system to kill and clear the bacteria.
The Company competes with Celgene, Novartis, Incyte Corporation, Millenium Pharmaceuticals, Inc., Stemline Therapeutics, Inc., Kura Oncology, Inc. and Amgen Inc.
KaloBios Pharmaceuticals Inc
1000 Marina Blvd Ste 250
BRISBANE CA 94005-1878
Company Web Links
- BRIEF-Kalobios Pharmaceuticals appoints David Tousley as interim CFO
- BRIEF-Kalobios Pharma says appointed Morgan Lam as chief scientific officer
- BRIEF-KaloBios Pharmaceuticals announces Martin Shkreli'S sale of his stake in the company
- BRIEF-Martin Shkreli dissolves stake in Kalobios Pharmaceuticals
- BRIEF-Kalobios Pharmaceuticals files for non-timely 10-Q